<DOC>
	<DOCNO>NCT00005962</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody gemtuzumab ozogamicin locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Combining one drug combine monoclonal antibody chemotherapy may kill cancer cell . It yet know treatment regimen effective acute myelogenous leukemia . PURPOSE : Randomized phase II trial compare effectiveness three treatment regimen treat patient relapsed refractory acute myelogenous leukemia .</brief_summary>
	<brief_title>Comparison Three Treatment Regimens Treating Patients With Relapsed Refractory Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare rate complete response ( CR ) CR without full platelet recovery patient relapse refractory acute myelogenous leukemia treat gemtuzumab ozogamicin cytarabine v daunorubicin liposomal cytarabine v cyclophosphamide , cytarabine , topotecan . - Compare toxicities 3 regimen patient . OUTLINE : This randomize , multicenter study . Patients stratify disease status ( relapse le 6 month first complete response ( CR ) v relapse 6-12 month first CR v refractory conventional initial induction chemotherapy ( 2 course ) first reinduction ( 1 course ) v second great relapse ) . - Induction : Patients randomize 1 3 treatment arm : - Arm I : Patients receive cytarabine IV 2 hour day 1-4 gemtuzumab ozogamicin IV 2 hour day 5 . - Arm II : Patients receive daunorubicin liposomal IV minimum 2 hour day 1-3 cytarabine IV 2 hour ( begin immediately completion daunorubicin liposomal infusion ) day 1-4 . - Arm III : Patients receive cyclophosphamide IV 1 hour every 12 hour day 1-3 , cytarabine IV 2 hour ( begin immediately completion cyclophosphamide infusion ) day 2-6 , topotecan IV continuously day 2-6 . - Consolidation : Patients achieve complete remission ( CR ) receive 1 additional course induction therapy arm originally randomize begin within 4-6 week initial documentation CR . Patients arm II receive additional daunorubicin liposomal rest ejection fraction le 50 % preconsolidation . All patient receive sargramostim ( GM-CSF ) IV 4 hour SQ daily begin 24 hour completion consolidation therapy continue blood count recover . Patients follow every 3 month year 2 , every 6 month year 5 , annually thereafter death . PROJECTED ACCRUAL : A maximum 150-165 patient ( 50-55 per arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven acute myelogenous leukemia one follow type : Acute myeloblastic leukemia ( FAB type M0 , M1 , M2 ) Acute promyelocytic leukemia ( FAB type M3 ) allow ineligible ECOG M3 protocol tretinoin arsenic trioxide therapy plan Acute myelomonocytic leukemia ( FAB type M4 ) Acute monocytic leukemia ( FAB type M5 ) Acute erythroleukemia ( FAB type M6 ) Acute megakaryocytic leukemia ( FAB type M7 ) Must meet 1 follow criterion : Relapse le 6 month first complete remission ( CR ) Relapse 612 month first CR Refractory conventional initial induction chemotherapy ( 2 course ) first reinduction ( 1 course ) Must marrow documentation residual leukemia chemotherapy ( least 2 week duration ) Second great relapse No relapse great 1 year achieve first CR Blast cell must CD33 positive Prior CNS leukemia allow currently documentation CNS involvement CSF examination ( i.e. , negative CSF lumbar puncture ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL* SGOT le 2 time upper limit normal* NOTE : *Unless due leukemia infiltration Renal : Creatinine great 2.0 mg/dL Cardiovascular : See Chemotherapy No myocardial infarction within past 3 month No significant congestive heart failure No significant cardiac arrhythmia Cardiac ejection fraction normal MUGA scan echocardiogram Resting ejection fraction least 50 % least 5 % increase exercise Shortening fraction least 24 % normal echocardiogram Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent organ damage medical problem would precludestudy therapy No concurrent evidence ( include positive blood deep tissue culture stain ) invasive fungal infection No hypersensitivity ingredient gemtuzumab ozogamicin daunorubicin liposomal No active tumor would interfere study therapy increase risk PRIOR CONCURRENT THERAPY : Biologic therapy : No prior gemtuzumab ozogamicin Chemotherapy : See Disease Characteristics See Biologic therapy No prior daunorubicin liposomal topotecan Prior doxorubicin ( great 300 mg/m2 ) , daunorubicin ( great 300 mg/m2 ) , idarubicin ( great 100 mg/m2 ) , mitoxantrone ( great 100 mg/m2 ) allow left ventricular function adequate At least 4 week since prior chemotherapy except patient refractory conventional initial induction chemotherapy Prior hydroxyurea allow within 4 week prior begin study Hydroxyurea must discontinue least 24 hour prior begin study Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy except patient refractory conventional initial induction chemotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>